Moore Capital Management’s Insmed INSM Stock Holding History

Moore Capital Management’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5,000	Closed	-$335K	–	514
2024 Q2	$335K	Buy	+5,000	New	+$194K	0.01%	358
2023 Q4	–	Sell	-50,000	Closed	-$1.26M	–	490
2023 Q3	$1.26M	Buy	+50,000	New	+$1.14M	0.02%	278
2022 Q4	–	Sell	-119,972	Closed	-$2.58M	–	588
2022 Q3	$2.58M	Buy	+119,972	New	+$2.88M	0.06%	304
2020 Q1	–	Sell	-75,000	Closed	-$1.79M	–	217
2019 Q4	$1.79M	Sell	75,000 -25,000	-25%	-$509K	0.06%	195
2019 Q3	$1.76M	Hold	100,000	–	–	0.07%	217
2019 Q2	$2.56M	Buy	+100,000	New	+$2.79M	0.06%	218
2017 Q4	–	Sell	-50,000	Closed	-$1.56M	–	269
2017 Q3	$1.56M	Buy	50,000 +25,000	+100%	+$476K	0.03%	172
2017 Q2	$429K	Buy	+25,000	New	+$427K	0.01%	180

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Moore Capital Management's INSM Position: Q3 2024 in Review

Moore Capital Management sold out of Insmed (INSM) in Q3 2024, closing a stake of 5,000 shares — an estimated $335K sold.

Moore Capital Management first reported a position in INSM in Q2 2017 and held it in 8 quarters. The position peaked at $2.58M in Q3 2022. 413 funds tracked by Wall St. Rank hold INSM as of Q3 2024.

Moore Capital Management reported no remaining Insmed position as of Q3 2024 after selling out during the quarter.
Moore Capital Management sold 5,000 Insmed shares in Q3 2024, an estimated $335K.
Moore Capital Management first reported a position in Insmed in Q2 2017 and held it in 8 quarters.
Moore Capital Management's Insmed position peaked at $2.58M in Q3 2022.
413 funds tracked by Wall St. Rank held Insmed as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.